Journal article
Modified-Release Recombinant Human TSH (MRrhTSH) Augments the Effect of 131I Therapy in Benign Multinodular Goiter: Results from a Multicenter International, Randomized, Placebo-Controlled Study
Abstract
BACKGROUND: Recombinant human TSH (rhTSH) can be used to enhance (131)I therapy for shrinkage of multinodular goiter (MG).
OBJECTIVE, DESIGN, AND SETTING: The objective of the study was to compare the efficacy and safety of 0.01 and 0.03 mg modified-release (MR) rhTSH as an adjuvant to (131)I therapy, vs. (131)I alone, in a randomized, placebo-controlled, international, multicenter study.
Authors
Graf H; Fast S; Pacini F; Pinchera A; Leung A; Vaisman M; Reiners C; Wemeau JL; Huysmans D; Harper W
Journal
The Journal of Clinical Endocrinology & Metabolism, Vol. 96, No. 5, pp. 1368–1376
Publisher
The Endocrine Society
Publication Date
May 2011
DOI
10.1210/jc.2010-1193
ISSN
0021-972X